Shots: The US FDA has granted approval to Mavyret for shortening the treatment duration from 12 to 8wks. in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes […]readmore
Shots: The marketing authorization is based on P-IIIb EXPEDITION-8 study assessing Maviret in 280 treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks. The P-IIIb […]readmore
Shots: The approval follows the clinical study results assessing Mavyret (glecaprevir & pibrentasvir) in 47 children aged 12-17 yrs. with genotype 1, 2, 3 or 4 HCV infection without/mild Cirrhosis […]readmore
Copyright © 2020 Digiqole. All Right Reserved.